Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Advanced Solid Tumors
NCT02048709
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
22
Enrollment
INDUSTRY
Sponsor class
Conditions
Solid Tumor
Interventions
DRUG:
GDC-0919
Sponsor
Genentech, Inc.